These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30828962)

  • 1. Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010-2017.
    Dennis JM; Henley WE; McGovern AP; Farmer AJ; Sattar N; Holman RR; Pearson ER; Hattersley AT; Shields BM; Jones AG;
    Diabetes Obes Metab; 2019 Jul; 21(7):1576-1584. PubMed ID: 30828962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.
    Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M
    Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving type 2 diabetes mellitus glycaemic outcomes is possible without spending more on medication: Lessons from the UK National Diabetes Audit.
    Heald AH; Livingston M; Malipatil N; Becher M; Craig J; Stedman M; Fryer AA
    Diabetes Obes Metab; 2018 Jan; 20(1):185-194. PubMed ID: 28730750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of a sodium-glucose co-transporter-2 inhibitor versus placebo as an add-on therapy for people with type 2 diabetes inadequately treated with metformin and a dipeptidyl peptidase-4 inhibitor: a systematic review and meta-analysis of randomised controlled trials.
    De Buitléir C; O' Connor E; Satti MM; Shaw J; Liew A
    Diabet Med; 2021 Feb; 38(2):e14409. PubMed ID: 32979231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
    Nauck MA; Del Prato S; Durán-García S; Rohwedder K; Langkilde AM; Sugg J; Parikh SJ
    Diabetes Obes Metab; 2014 Nov; 16(11):1111-20. PubMed ID: 24919526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of anti-diabetic medication use in patients with type 2 diabetes mellitus in England and Wales.
    Datta-Nemdharry P; Thomson A; Beynon J; Donegan K
    Pharmacoepidemiol Drug Saf; 2017 Feb; 26(2):127-135. PubMed ID: 27642000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effects of sulphonylureas, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors added to metformin monotherapy: a propensity-score matched cohort study in UK primary care.
    Wilkinson S; Williamson E; Pokrajac A; Fogarty D; Stirnadel-Farrant H; Smeeth L; Douglas IJ; Tomlinson LA
    Diabetes Obes Metab; 2020 May; 22(5):847-856. PubMed ID: 31957254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017.
    Curtis HJ; Dennis JM; Shields BM; Walker AJ; Bacon S; Hattersley AT; Jones AG; Goldacre B
    Diabetes Obes Metab; 2018 Sep; 20(9):2159-2168. PubMed ID: 29732725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes.
    Owens DR; Bolli GB; Charbonnel B; Haak T; Landgraf W; Porcellati F; Traylor L; Kautzky-Willer A
    Diabetes Obes Metab; 2017 Nov; 19(11):1546-1554. PubMed ID: 28449412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: A 12-month comparison by concomitant sulphonylurea and/or glinide use.
    Terauchi Y; Riddle MC; Hirose T; Koyama M; Cheng X; Takahashi Y; Bolli GB
    Diabetes Obes Metab; 2018 Nov; 20(11):2541-2550. PubMed ID: 29888454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in incidence of severe hypoglycaemia in people with type 2 diabetes from 2006 to 2016: analysis based on health insurance data in Germany considering the anti-hyperglycaemic medication.
    Müller N; Lehmann T; Klöss A; Günster C; Kloos C; Müller UA
    Diabet Med; 2020 Aug; 37(8):1326-1332. PubMed ID: 32145093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Route to improving Type 1 diabetes mellitus glycaemic outcomes: real-world evidence taken from the National Diabetes Audit.
    Heald AH; Livingston M; Fryer A; Moreno GYC; Malipatil N; Gadsby R; Ollier W; Lunt M; Stedman M; Young RJ
    Diabet Med; 2018 Jan; 35(1):63-71. PubMed ID: 29120503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Management of hyperglycaemia in type 2 diabetes: a patient-centered approach].
    Scheen AJ; Mathieu C
    Rev Med Liege; 2012 Dec; 67(12):623-31. PubMed ID: 23342872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of treatment modification before and after implementation of the updated 2015 NICE guideline on type 2 diabetes: A retrospective cohort study.
    van Dalem J; Brouwers MCGJ; Burden AM; Stehouwer CDA; Klungel OH; de Vries F; Driessen JHM
    Diabetes Res Clin Pract; 2021 Jun; 176():108828. PubMed ID: 33894280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications.
    Desai NR; Shrank WH; Fischer MA; Avorn J; Liberman JN; Schneeweiss S; Pakes J; Brennan TA; Choudhry NK
    Am J Med; 2012 Mar; 125(3):302.e1-7. PubMed ID: 22340932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.
    Zaccardi F; Dhalwani NN; Dales J; Mani H; Khunti K; Davies MJ; Webb DR
    Diabetes Obes Metab; 2018 Apr; 20(4):985-997. PubMed ID: 29205774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.